News-Novamab

Our Story

The latest information

Our Story

News

Novamab Announces China Phase Ⅱ Clinical Trial Approval for First-in-Class Inhaled IL-4Rα VHH Antibody LQ036 Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD)

Exclusive interview with Dr. Wan Yakun: the fifth anniversary of Novamab, the next goal is Ablynx

Wan Yakun of Novamab: Dream of Zhangjiang Science City, and brave the difficulties of nanoantibody pharmaceutical

Novamab | Five years of joint efforts to start a new journey

Novamab won the support of Shanghai's 2022 annual innovation fund plan

Novamab was listed in "Top 100 Chinese pharmaceutical innovative seed enterprises in 2022"

Novamab Biological announced the appointment of Ms. Huang Jing as the company's chief business officer

Novamab won the nomination award of "Star of the Future" in biomedicine

Celebrate the official commencement of GMP production!

Novamab participated in the development of COVID-19 neutralizing antibody molecular imaging technology, and the research results were published in Research!

The research achievements on COVID-19 by Novamab and Professor Li Henan of Jiangsu University were published in the international journal Analytica Chimica Acta!

Total 58 1 2 345 6